> For the complete documentation index, see [llms.txt](https://www.thiamine.wiki/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.thiamine.wiki/biochemistry/thiamine-derivatives-1.md).

# thiamine derivatives

{% hint style="info" %}
**Section:** Complete Biochemistry → Thiamine Derivatives\
**Reading level:** Technical, with a plain-language summary\
**Last reviewed:** October 2026 · **Evidence status:** Moderate (pharmacokinetics); limited to mixed (clinical outcomes, labelled per compound)
{% endhint %}

## Summary

Ordinary thiamine is a charged molecule that relies on saturable transporters to cross membranes. Beginning in the 1950s, mainly in Japan, chemists developed **thiamine derivatives** designed to be absorbed more efficiently. Almost all of them share one chemical trick: they are versions of thiamine in which the **thiazolium ring has been opened and "locked"** by attaching a group to the sulfur atom. This removes the permanent positive charge. Once inside the body, the lock is removed, the ring closes and ordinary thiamine is released.

Derivatives reliably produce **higher blood thiamine levels** than equivalent amounts of thiamine salts. They differ from each other in chemistry, in where they deliver thiamine (for example, whether they raise brain levels), and possibly in effects that are not explained by thiamine delivery alone. Clinical evidence varies from **reasonable** (some benfotiamine trials) to **very limited or absent** (several newer or less-studied compounds).

{% hint style="info" %}
**Naming:** this wiki uses generic chemical names (and international non-proprietary names, where they exist) rather than brand names.
{% endhint %}

## Why derivatives were developed

* **Saturable absorption:** at dietary doses, thiamine uptake depends on the THTR-1 and THTR-2 transporters (see [Thiamine Transporters](broken://pages/e114cfc2a7f363a679ae103c52c9089e5d2d0b24)).
* **Beriberi in Japan:** a long history of thiamine deficiency drove Japanese research into better-absorbed forms.
* **A natural lead:** in the early 1950s, Motonori Fujiwara and colleagues in Kyoto found that thiamine reacts with allicin from garlic to form **allithiamine**, a lipid-soluble disulfide that was better absorbed than thiamine. This discovery launched the development of synthetic analogues.

## The key chemical idea

{% stepper %}
{% step %}

### Open the thiazolium ring

At alkaline pH, the thiazolium ring of thiamine can open to an uncharged **thiol form** (see [Thiamine Structure](broken://pages/e97e22d3de70d018c7c19aa407e5feb03d96c2a0)).
{% endstep %}

{% step %}

### Trap the open form

Derivatives **trap** this open form by attaching a group to the sulfur:

* through a **disulfide bond** (S–S) in the disulfide derivatives;
* through a **thioester bond** (S–CO–R) in the S-acyl derivatives;
* or as a **cyclic thiocarbonate**.
  {% endstep %}

{% step %}

### Cross membranes

Without the positive charge, many derivatives can cross membranes by **passive diffusion**, independently of thiamine transporters.
{% endstep %}

{% step %}

### Release thiamine

Inside the body, **disulfides are reduced** (by glutathione and other thiol systems) and **thioesters are hydrolysed** (by thioesterases). This releases the thiol form, which closes spontaneously at physiological pH to give **thiamine**.
{% endstep %}

{% step %}

### Phosphorylate thiamine

Thiamine is then phosphorylated by TPK1 to TPP as usual.
{% endstep %}
{% endstepper %}

## Classes and main compounds

| Compound                                           | Class                             | Description                                                                   | Origin                                                        |
| -------------------------------------------------- | --------------------------------- | ----------------------------------------------------------------------------- | ------------------------------------------------------------- |
| **Allithiamine**                                   | Disulfide                         | Thiamine allyl disulfide                                                      | Natural (garlic and *Allium* species); discovered early 1950s |
| **Prosultiamine** (thiamine propyl disulfide, TPD) | Disulfide                         | Propyl disulfide analogue                                                     | Synthetic, Japan                                              |
| **Fursultiamine** (TTFD)                           | Disulfide                         | Thiamine tetrahydrofurfuryl disulfide                                         | Synthetic, Japan, 1960s                                       |
| **Sulbutiamine**                                   | Disulfide (dimer)                 | Two O-isobutyryl thiamine units joined by a disulfide                         | Synthetic, Japan                                              |
| **Bisbentiamine**                                  | Disulfide (dimer)                 | O-benzoyl thiamine disulfide                                                  | Synthetic, Japan                                              |
| **Thiamine disulfide**                             | Disulfide (dimer)                 | Two open-form thiamine molecules linked by S–S                                | Natural oxidation product; also used as a drug                |
| **Benfotiamine**                                   | S-acyl (thioester) with phosphate | S-benzoylthiamine O-monophosphate                                             | Synthetic, Japan, late 1950s                                  |
| **Dibenzoylthiamine** (DBT)                        | O,S-diacyl (thioester + ester)    | O,S-dibenzoylthiamine                                                         | Synthetic, Japan; renewed research interest since \~2020      |
| **Cetotiamine**                                    | O,S-diacyl (carbonate)            | O,S-diethoxycarbonylthiamine                                                  | Synthetic, Japan                                              |
| **Cycotiamine** (cyclocarbothiamine)               | Cyclic thiocarbonate              | Open-form thiamine with sulfur and oxygen joined in a 1,3-oxathian-2-one ring | Synthetic, Japan, 1960s                                       |

## Comparative pharmacology

| Compound                 | Absorption                                                                 | Blood thiamine                                     | Brain thiamine (animal data)                             | Notes                                                                                 |
| ------------------------ | -------------------------------------------------------------------------- | -------------------------------------------------- | -------------------------------------------------------- | ------------------------------------------------------------------------------------- |
| **Thiamine salts**       | Carrier-mediated at low doses; diffusion at high doses                     | Baseline comparator                                | Regulated by transporters                                | See [Thiamine Salts & Forms](broken://pages/195dbfe1a7b6057fdd11ed68497447f385cde310) |
| **Benfotiamine**         | Dephosphorylated in the gut to lipophilic S-benzoylthiamine, then absorbed | Highest of the compounds compared in human studies | **Little or no increase** in mice                        | Not lipid-soluble itself; poorly soluble in water and organic solvents                |
| **Fursultiamine (TTFD)** | Lipophilic; passive diffusion                                              | Higher than thiamine salts                         | Increases reported                                       | Garlic-like odour                                                                     |
| **Sulbutiamine**         | Highly lipophilic                                                          | Higher than thiamine salts                         | **Increases** thiamine and phosphate esters in rat brain | Developed for central effects                                                         |
| **Dibenzoylthiamine**    | Lipophilic                                                                 | Higher than thiamine in mice                       | Data limited                                             | Mainly preclinical                                                                    |

In a human crossover study comparing oral derivatives, **benfotiamine produced the highest plasma and erythrocyte thiamine levels**, followed by fursultiamine, and then thiamine disulfide.

{% hint style="warning" %}
**Two common misconceptions:**

1. **"Benfotiamine is a fat-soluble disulfide."** It is neither. It is an S-acyl phosphate derivative that is poorly soluble in both water and oils. It becomes lipophilic only after the phosphate is removed in the gut. Its pharmacology differs from that of the disulfides.
2. **"Higher blood levels mean better results."** Blood levels show delivery, not benefit. Different compounds deliver thiamine to different tissues, and some effects may not depend on thiamine delivery at all.
   {% endhint %}

## Beyond thiamine delivery

Several studies, mainly in cells and rodents, report that thioester derivatives (benfotiamine and dibenzoylthiamine) have **antioxidant and anti-inflammatory effects** that do not appear to be explained by increases in TPP or TPP-dependent enzyme activity. Proposed explanations include:

* activation of the **Nrf2** antioxidant pathway;
* effects of as-yet-unidentified **open-thiazole-ring metabolites**;
* modulation of signalling enzymes such as **GSK-3β**.

These mechanisms are **preclinical hypotheses**. The active metabolites have not been identified.

## Clinical evidence at a glance

| Compound                 | Best clinical evidence                                                                                                                | Overall assessment                                                                                                       |
| ------------------------ | ------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------ |
| **Benfotiamine**         | Several randomized controlled trials (diabetic neuropathy, nephropathy, Alzheimer's disease); a larger Alzheimer's trial is under way | **Mixed**: some symptomatic benefits in short neuropathy trials; no effect on objective outcomes in longer trials so far |
| **Fursultiamine (TTFD)** | Small open-label studies; long clinical use in Japan                                                                                  | **Limited**                                                                                                              |
| **Sulbutiamine**         | Older trials in fatigue (asthenia); small open-label studies                                                                          | **Limited**                                                                                                              |
| **Prosultiamine**        | Small open-label trial in HTLV-1-associated myelopathy                                                                                | **Limited**                                                                                                              |
| **Dibenzoylthiamine**    | No published controlled human trials found as of October 2026                                                                         | **Preclinical only**                                                                                                     |
| **Others**               | Little modern published research                                                                                                      | **Very limited**                                                                                                         |

## Safety overview

* Thiamine derivatives have generally been **well tolerated** in published studies, including benfotiamine for up to 12–24 months.
* **Long-term safety data are much more limited** than for thiamine itself, especially for sulbutiamine and dibenzoylthiamine.
* Disulfides release thiol by-products (for example, tetrahydrofurfuryl mercaptan from TTFD), which can cause a garlic-like odour.
* Regulatory status varies: some derivatives are licensed medicines in some countries and sold as supplements in others.

## Pages in this section

* [Benfotiamine](broken://pages/75effe2f75d8702a4645b72eb76b7a3b69392e6d)
* [Thiamine Tetrahydrofurfuryl Disulfide (TTFD)](broken://pages/d037fc57c35a037bf0b6fdbf558c95ab9a21412f)
* [Dibenzoylthiamine (DBT)](broken://pages/61b9d87ea2cbca6001a269c28ff14a79807693f2)
* [Sulbutiamine](broken://pages/03906e8b2674229295f1625dddf1cfbb518b9b6b)
* [Novel Derivatives & Future Research](broken://pages/5779c77edc96f4b8ba8c060eacc5bbbbb1df0b1f)

## Open questions

* Which derivative, if any, best delivers thiamine to the human brain?
* Which effects are due to thiamine delivery, and which to other metabolites?
* How do derivatives compare head-to-head on clinical outcomes? Such trials are almost entirely lacking.
* What are the long-term safety profiles of the less-studied compounds?

## Related pages

* [Thiamine Structure](broken://pages/e97e22d3de70d018c7c19aa407e5feb03d96c2a0)
* [Thiamine Transporters](broken://pages/e114cfc2a7f363a679ae103c52c9089e5d2d0b24)
* [Mechanisms of Malabsorption](broken://pages/2a0d5d46380717fcf2639e31a45f31d244f053a8)
* [Common Misconceptions](broken://pages/5e66ed178e30898e5bae62adad9e27fc291320a5)

## References

1. Fujiwara M. Allithiamine and its properties. *Journal of Nutritional Science and Vitaminology*. 1976;22(Suppl):57–62.
2. Lonsdale D. Thiamine tetrahydrofurfuryl disulfide: a little known therapeutic agent. *Medical Science Monitor*. 2004;10(9):RA199–RA203.
3. Bitsch R, et al. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamin derivative. *Annals of Nutrition and Metabolism*. 1991;35(5):292–296.
4. Greb A, Bitsch R. Comparative bioavailability of various thiamine derivatives after oral administration. *International Journal of Clinical Pharmacology and Therapeutics*. 1998;36(4):216–221.
5. Volvert ML, et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. *BMC Pharmacology*. 2008;8:10.
6. Bettendorff L, et al. Injectable sulbutiamine induces an increase in thiamine concentrations and thiamine phosphate esters in rat brain. *Biochemical Pharmacology*. 1990;40(11):2557–2560.
7. Sambon M, Wins P, Bettendorff L. Neuroprotective effects of thiamine and precursors with higher bioavailability: focus on benfotiamine and dibenzoylthiamine. *International Journal of Molecular Sciences*. 2021;22(11):5418.
8. \[Authors to be confirmed]. Synthetic thioesters of thiamine: promising tools for slowing progression of neurodegenerative diseases. *International Journal of Molecular Sciences*. 2023;24(14):11296.
9. Nakamura T, et al. Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial. *BMC Medicine*. 2013;11:182.

{% hint style="info" %}
**Editorial note:** This page describes mechanisms and published evidence. It is not medical advice and does not recommend doses. Suggest corrections or new sources via the feedback link.
{% endhint %}
